Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

By R. Bresalier, R. Sandler, H. Quan, J. Bolognese, B. Oxenius, K. Horgan, C. Lines, R. Riddell, D. Morton, Á. Lanas and 2 more. New England Journal of Medicine, 2005

2,605 citations recorded by the source corpus.

Subfields: Oncology, Pharmacology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/288d3c9b4a76e245fec2e28a87b2e0d1bd7d7078

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Sebastian Schneeweiss
2. Prashanth Rawla

In Pharmacology

1. P. Rao
2. Dingzhi Wang
3. K. Thygesen
4. R. Dubois
5. E. Knaus

Citations in the corpus

• Therapeutic targeting of the tumor microenvironment. (2005, neutral): “However, the current controversy surrounding the association of long-term high-dose COX-2 inhibitor use with an elevated risk of cardio­ vascular events (Bresalier et al., 2005) indicates that alternative drugs or molecular targets will need to be identified.”
• Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. (2014, neutral): “…trial, comparing 25 mg /day rofecoxib (n = 1287) dose with placebo (n=1299) in 2586 colorectal adenoma patients after 18 months of treatment also reported a greater risk of MI infarctions and ischemic cerebrovascular, congestive heart failure, and cardiac failure events for rofecoxib (131).”
• The Role of COX-2 in Intestinal Inflammation and Colorectal Cancer (2009, positive): “, 2006) and the Adenomatous Polyp Prevention on Vioxx (APPROVe) trial (Bresalier et al., 2005), were performed and showed that COXIBs prevent recurrence of sporadic adenomas with an increase in cardiovascular events.”
• Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics (2006, background): “A year later a large randomized controlled trial of rofecoxib confirmed the elevated risk in a healthier and younger population.(40) The additional estimation error of OREC from the validation study can be incorporated in the overall error term.”
• Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. (2006, result): “In October 2004, rofecoxib was withdrawn from world markets after a randomized placebo-controlled trial found that in doses of 25 mg/d, it increased rates of cardiovascular events in patients with colorectal polyps.(1) The results were confirmed by several large pharmacoepidemiological studies.”